Exparel Uses for Postoperative Analgesia
Exparel (liposomal bupivacaine) is FDA-approved for local infiltration in patients ≥6 years old and for specific peripheral nerve blocks in adults: interscalene brachial plexus block, sciatic nerve block in the popliteal fossa, and adductor canal block. 1
FDA-Approved Indications
Local Infiltration
- Adults: Up to 266 mg maximum dose administered directly into the surgical site 1
- Pediatric patients (6 to <17 years): 4 mg/kg, maximum 266 mg 1
- Single administration only; cannot be substituted with other bupivacaine formulations even at equivalent strengths 1
Regional Nerve Blocks (Adults Only)
The following three nerve blocks are the only FDA-approved regional techniques for Exparel 1:
- Interscalene brachial plexus nerve block: 133 mg dose
- Sciatic nerve block (popliteal fossa): 133 mg dose
- Adductor canal block: 133 mg (10 mL) mixed with 50 mg (10 mL) of 0.5% bupivacaine HCl for total 20 mL volume
Critical limitation: The FDA explicitly states that safety and effectiveness have not been established for any other nerve blocks beyond these three specific techniques 1
Clinical Context and Multimodal Analgesia Integration
Exparel fits into contemporary perioperative pain management as part of multimodal analgesia protocols. The 2026 ASA guidelines emphasize procedure-specific approaches using regional analgesia (particularly fascial plane blocks) with local anesthetics like bupivacaine and ropivacaine for cardiothoracic, mastectomy, and abdominal surgeries 2. While these guidelines discuss bupivacaine broadly, they do not specifically address the liposomal formulation.
Key Surgical Applications Reported in Literature
- Orthopedic surgery: Periarticular infiltration for hip and knee arthroplasty 3, 4
- Plastic surgery: Breast reconstruction, augmentation, abdominoplasty 5
- Dermatologic surgery: Excisions and Mohs surgery 6
- ENT procedures: Adult tonsillectomy 7
Important Clinical Caveats
What NOT to Do
- Do not dilute with water or hypotonic solutions 1
- Avoid additional local anesthetics within 96 hours after Exparel administration 1
- Do not use for obstetrical paracervical block (contraindicated) 1
- Do not attempt to convert doses from other bupivacaine products to Exparel 1
Monitoring Requirements
- Monitor cardiovascular and neurological status during and after injection 1
- Use cautiously in hepatic disease patients (amide local anesthetics are hepatically metabolized) 1
- Watch for methemoglobinemia, though rare 1
Evidence Quality Considerations
The evidence supporting Exparel's superiority over standard local anesthetics is mixed and controversial. A comprehensive 2021 systematic review of 76 randomized controlled trials found that only 11% (4 of 36) of infiltration studies showed clinically relevant improvement favoring liposomal bupivacaine over unencapsulated bupivacaine or ropivacaine 8. Notably, 92% of trials (11 of 12) suggested peripheral nerve blocks with standard bupivacaine provided superior analgesia to infiltrated liposomal bupivacaine 8.
Critical bias concern: Among high-risk-of-bias trials, 84% reported statistically significant results favoring Exparel, compared to only 14% of low-risk-of-bias trials 8. This suggests publication bias and industry influence may inflate perceived benefits.
Practical Clinical Positioning
Despite mixed comparative efficacy data, Exparel provides extended-duration analgesia (up to 72-96 hours) from a single administration 9, 4. This may reduce opioid consumption in select patients and procedures, particularly when standard multimodal approaches are insufficient. Recent 2026 data in adult tonsillectomy showed statistically significant reductions in pain scores at postoperative day 3 and decreased oxycodone use between days 3-5 7.
Use Exparel when: Extended analgesia duration justifies the significantly higher cost compared to standard bupivacaine, particularly in procedures with predictable severe postoperative pain where opioid minimization is a priority and the patient cannot receive continuous nerve block catheters.